Research Lab Applies to Import Ibogaine and Marijuana
Published Date: 6/17/2026
Notice
Summary
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Importer application could supply researchers
Scottsdale Research Institute applied on May 19, 2026 to register as an importer of Schedule I bulk active pharmaceutical ingredients for ibogaine (drug code 7260), marihuana (7360), and 3,4‑Methylenedioxymethamphetamine/MDMA (7405). The company says it plans to import these bulk APIs to support clinical research by Schedule I registrants.
Synthetic cannabidiol imported under marijuana code
For the marihuana drug code (7360), Scottsdale Research Institute plans specifically to import a synthetic cannabidiol as a bulk active pharmaceutical ingredient. That import would be intended to support clinical research by Schedule I registrants.
Registration excludes finished drug imports for sale
The notice states that approval of this importer registration will not authorize importation of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. The registrant’s authorization is limited to the activities allowed under 21 U.S.C. 952(a)(2).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-12138, Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc., also known as PCI Pharma Services, wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs under government rules. People who make or use these drugs can share their thoughts or ask for a hearing by July 17, 2026, so keep an eye on that deadline!
Next: 2026-12141, Importer of Controlled Substances Application: Veranova, L.P.
Veranova, L.P. wants to become an official importer of certain controlled substances like coca leaves and opium. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could shake up the drug import scene and might affect how these substances are handled and tracked.